Recovery and Muscle Function After Supplementation With Turmeric (RECOFAST)

December 9, 2022 updated by: Naturex SA

A Placebo Controlled, Randomised, Crossover Clinical Trial to Evaluate the Effect of Turmipure Gold® in Muscle Pain and Function Recovery in Moderately Active Adults

The objective of the study is to test the capacity of a five-day supplementation of Turmipure Gold® to improve exercise-induced muscle pain and function recovery in moderately active adults after exercise-induced muscle damage

Study Overview

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cork, Ireland, T23 R50R
        • Atlantia Food Clinical Trials

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy free-living males
  • Age: 25-45 years old
  • Have a BMI between 18.5 and 28 kg/m²
  • Moderately active with running 15-20 km per week
  • With 1 to 4h of training per week, with maximum 1h of lower body heavy-load or resistance training (e.g., Hill running or hiking, HIT exercise, Squats, Lunges, Leg-press, Bench steps, etc.)
  • Consent to the study protocol and to comply with study product
  • Willing to limit caffeine, smoking, and alcohol consumption during the entire study period with no more than 5 cigarettes per day and 2 drinks. Also, alcohol consumption will not be allowed 24hours prior to exercise-induced muscular damage
  • Willing to refrain from training for 3 days before the first test, 5 days before each damage-inducing exercise and during each supplementation phase, including active recovery exercises such as swimming, cycling at low intensity, unusual distance walking (however such should be encouraged during the 14 days wash-out)
  • Willing to refrain the use of anti-inflammatory/pain reliever drugs such as paracetamol, NSAIDs, etc., during each supplementation phase, from 24 hours prior to 72 hours following the exercise-induced muscular damage
  • Willing to refrain from 'recovery' treatments over the 72 hours following the damage inducing exercise such as:

    1. Hydrotherapy - cold water immersion, hot water immersion, or contrast therapy (as well as Jacuzzis, Steam baths, or Saunas)
    2. Massage - self, foam rolling, etc.
    3. Stretching
    4. Compression garments
    5. Topical applications - Tiger Balm, Deep Heat etc.

Exclusion Criteria:

  • Participants with any indicators of arthritis, joint disorders chronic pain syndrome, muscle disorder diseases (e.g., fibromyalgia, etc.)
  • History of surgery or significant injury in joints or in the lower limb in the last six months prior to study enrolment, or an anticipated need for surgical or invasive procedure that will be performed during the study
  • Using omega-3-fatty acid, probiotic supplements, vitamins, minerals, or any dietary supplements (including botanicals), especially to maintain joint health 4 weeks prior to screening and during the entire study. Potential supplements include but are not limited to Beta-alanine, Creatine, HMB, Carnosine, Taurine, androstenedione, DHEA, Whey protein, or a pre-workout supplement
  • Following any specific diet such as high-protein, vegetarian, vegan, etc
  • Taking any drugs such as antibiotics, laxatives, or immunosuppressant drugs
  • History of glucocorticoid injection or hyaluronic acid injections within 3 months prior to enrolment
  • Participants near or in the peak of training for an athletic race (half or marathon, cycling tour or triathlon)
  • History or current significant cardiovascular, pulmonary, renal, liver, digestive (including an inflammatory bowel disease), infectious disease, systemic disease, immune disorder, or metabolic/endocrine disorders (including diabetes mellitus) or other disease that would preclude supplement ingestion and/or assessment of study objectives, including uncontrolled hypertension, uncontrolled thyroidism or lipidaemia that is not on stable medication for at least 3 months.
  • Participant has any concurrent medical or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements
  • Participant with history of drug and / or alcohol abuse at the time of enrolment
  • Any previous or current cancer diagnosis (including a benign or malign tumour of intestine or colon)
  • Current illnesses which could interfere with the study (e.g., prolonged severe diarrhoea, regurgitation/severe, difficulty swallowing)
  • Known allergy to components of the test product or sensitivity to herbal products or with a medical history of food allergies
  • Participants taking any anticoagulant or heparin treatment (including aspirin)
  • Clinically significant abnormal laboratory results at screening
  • Participant currently involved in any other clinical trial or having participated in a trial within 90 days prior to randomisation.
  • Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
  • History of non-compliance with medical treatments or recommendations.
  • Participants who are required to perform squatting motions or descend a lot of stairs in their daily work activities, which may be painful following the Exercise Induced Muscle Damage.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Randomized Crossover_Sequence 1
Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Placebo: colored acacia gum - 1 capsule per day - as prescribed
Other: Randomized Crossover_Sequence 2
Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Placebo: colored acacia gum - 1 capsule per day - as prescribed

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change on Perceived Muscle Soreness
Time Frame: 72 hours
Perceived Muscle Soreness in quadriceps during squatting activities assessed by VAS (0-100 mm, after two tries)
72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change on Muscle damage
Time Frame: 72 hours
Muscle damage assessed by circulating levels of Creatine kinase in blood samples
72 hours
Change on Isometric Muscle function recovery
Time Frame: 72 hours
Muscle function recovery assessed on quadriceps muscular function during isometric contractions recording the torque (Nm) using Biodex
72 hours
Change on Isokinetic Muscle function recovery
Time Frame: 72 hours
Muscle function recovery assessed on quadriceps muscular function during isokinetic extensions recording the torque (Nm) using Biodex
72 hours
Change on Muscle power recovery
Time Frame: 72 hours
Muscle power recovery assessed by Peak power (Watts) using vertical jump tests (best performance and average of 3 tries)
72 hours
Change on Muscle ROM recovery
Time Frame: 72 hours
Muscle ROM recovery assessed by Range Of Movement using a goniometer (knee flexion)
72 hours
Change on Perceived wellness and well-being
Time Frame: 72 hours
Perceived wellness and well-being is assessed by a psychometric test evaluating fatigue, sleep quality, general muscle soreness, stress, and mood (0-25, 25 indicating best feelings of wellness and well-being)
72 hours
Change on Perceived exertion during exercise
Time Frame: 30 min
Perceived exertion through breathing difficulty during exercise assessed by the Borg Rating of Perceived Exertion (0-10, 10 indicating maximal difficulty)
30 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Trevor Wood, PhD, Sport Physiologist University College Cork

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 12, 2021

Primary Completion (Actual)

April 1, 2022

Study Completion (Actual)

April 1, 2022

Study Registration Dates

First Submitted

June 21, 2021

First Submitted That Met QC Criteria

June 30, 2021

First Posted (Actual)

July 1, 2021

Study Record Updates

Last Update Posted (Estimate)

December 12, 2022

Last Update Submitted That Met QC Criteria

December 9, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Turmipure Gold®

Subscribe